1 Min Read
Ra Pharmaceuticals Inc:
* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.